NeuroMetrix Inc

NeuroMetrix — IPO Roadshow (November 2016)

22 slides from NeuroMetrix's IPO roadshow presentation, Nov 23, 2016

  1. Slide 1: NeuroMetrix Free Writing Prospectus, December 2016

    Nasdaq : NURO Shai N. Gozani, MD, PhD Tom Higgins President & CEO Chief Financial Officer December 2016 ISSUER FREE WRITING PROSPECTUS Filed Pursuant to Rule 433 Registration Statement No. 333 - 207566 Dated November 23, 2016

  2. Slide 2: Free Writing Prospectus

    2 Free Writing Prospectus NeuroMetrix , Inc. is providing this presentation which highlights basic information about the Company and the offering to which this communication relates. Because it is a summary, it does not contain all the information that should be considered before investing in our se

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement The statements contained in this corporate presentation include forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including, without

  4. Slide 4: Equity Offering Overview

    Equity Offering Overview • Issuer: • Exchange: • Offering Size • Securities Offered • Use of Proceeds: • Placement Agent: • NeuroMetrix , Inc • Nasdaq: NURO • $30.0 million • Class A Units – one share of common stock and a warrant to purchase one share of common stock at an exercise price of 110% of

  5. Slide 5: Overview

    Overview • Boston based healthcare company • Founded in 1996 as spin - off from MIT • Integrate bioelectrical and digital medicine to address chronic disease • Industry leading R&D capabilities • Experienced commercialization team • Market a first - in - class over - the - counter wearable device to

  6. Slide 6: Commercial Product Portfolio

    Commercial Product Portfolio Deep Technology & Market Foundation 6 Neuro - Diagnostics Neuro - Therapeutics ADVANCE™ Launched 2008 Winding down (orthopedics, diabetes) DPNCheck ® Launched 2012 (diabetes) SENSUS® Launched 2013 Winding down (chronic pain) Quell® Launched 2015 (chronic pain) Quell 59%

  7. Slide 7: Chronic Pain Market: Large Opportunity with Many Unmet Needs

    Chronic Pain Market Large Opportunity with Many Unmet Needs • 100M US adults, 1.5B worldwide – Low back pain, arthritis, diabetic nerve pain, fibromyalgia, cancer, CRPS, PHN, neck pain, facial pain • $600B annual cost in US 1 • $35B global market 2 • $20B annual out - of - pocket spending in US 3 •

  8. Slide 8: Quell TV Commercial

    Quell TV Commercial 8 NeuroMetrix, Inc. ©2016

  9. Slide 9: Quell Wearable Pain Relief Technology

    Quell Wearable Pain Relief Technology Widespread Chronic Pain Relief without Side Effects • High - power wearable neurostimulator • Fully automated intelligent stimulation control • Integrated digital health monitoring • Connected device • Rechargeable Lithium - Polymer (3 - 7 days) • Class II medic

  10. Slide 10: Mobile and Digital Medicine Strategy

    10 Mobile and Digital Medicine Strategy Enhance User Experience • iOS and Android apps • Quell app enhances user experience – Interactive therapy dashboard – Real - time control of device – Customize device settings – Therapy, sleep, activity, and pain monitoring – Electrode management & purchasing

  11. Slide 11: Quell Business Model

    Quell Business Model Devices Create Recurring Revenue Stream Electrodes: $29.95 (2 per package) Recurring Revenue Revenue Per User Every Three Months Every Month Year 1 $370 $610 Year 2+ $120 $360 Reorder Rate Starter Kit: $249 (device, 1 electrode package, sports band) 11 NeuroMetrix, Inc. ©2016

  12. Slide 12: Market Opportunity of 19M Chronic Pain Sufferers

    Market Opportunity of 19M Chronic Pain Sufferers 12 100M 19M Note. Market opportunity estimate independently developed by Connelly Partners (Boston, MA) using Nielsen MRI data. 2016. • Not migraine or headache • 40+ years of age • $75K+ household income • College educated • Active • Want to minimize

  13. Slide 13: North America Quell Distribution

    North America Quell Distribution 13 Consumer Professional e - commerce Retail (1500 stores) TV QuellRelief.com Chiro /PT Direct WBC Group NeuroMetrix, Inc. ©2016 Physicians Institutional (VA)

  14. Slide 14: Quell Demonstrating Consistent Growth

    Quell Demonstrating Consistent Growth 14 NeuroMetrix, Inc. ©2016 $602 $985 $1,478 $1,703 $2,534 $2,900 0 500 1000 1500 2000 2500 3000 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Invoiced Sales GAAP Revenue Deferred Revenue Sales & Revenue ($1000s) 2,607 4,514 6,675 8,138 11,201 12,086 0 2000 400

  15. Slide 15: Consumers Report Positive Experience With Quell

    Consumers Report Positive Experience With Quell 15 NeuroMetrix, Inc. ©2016 1 2 3 4 5 >100 Reviews <100 Reviews Expected 2 Note 1. Tabulated August 27, 2016 Note 2. Expected average rating based on clinical efficacy and return rate (75% with 4 or 5 stars and 25% with 1 or 2 stars). Average Customer S

  16. Slide 16: Quell Provides Therapeutic Benefit to ~80% of Subjects

    Quell Provides Therapeutic Benefit to 70 - 80% of Subjects • 81% of subjects reported improvement in chronic pain • 67% of subjects reported reduction in pain medication use 16 NeuroMetrix, Inc. ©2016 Gozani. Fixed - Site High - Frequency Transcutaneous Electrical Nerve Stimulation for Treatment of

  17. Slide 17: Quell has a Strong Competitive Position

    Quell has a Strong Competitive Position Benefits Quell ® OTC TENS 1 OTC Internal Analgesics 2 OTC External Analgesics 3 Non - narcotic Pain Meds 4 Opioid Pain Meds 5 Treats Chronic Pain +/ - +/ - +/ - Multi - Site Pain Relief Nighttime Pain Relief No Major Side Effects No Addiction Potential Smartph

  18. Slide 18: Intellectual Property

    Intellectual Property • 45 issued U.S. patents • 3 issued foreign patents • 34 pending patent applications – 17 U.S. applications – 17 foreign national applications • Wearable therapeutic technology (Quell) – 2 issued utility patents (US 8,948,876 and US 9,474,898) – 3 issued design patents – 30 pen

  19. Slide 19: Growth Strategy

    Growth Strategy • Expand retail distribution – Build on presence in pharmacy (CVS, Walgreens) and mass merchandisers (Target) – Move into new retail categories (electronics, club) • Product innovation – Aggressive product road - map, next product launch at CES 2017 – Decrease COGS, improve usability

  20. Slide 20: Financials

    Financials 20 NeuroMetrix , Inc. ©2016 Outstanding 5,318,273 Preferred, as-converted 10,892,929 16,211,202 Recent Closing Price $1.27 Market Value $20,588,227 Market Valuation (Nov 21, 2016) ($000's) Q3 2016 Q2 2016 Q1 2016 2015 2014 2013 Revenue $3,389 $2,647 $2,275 $7,300 $5,513 $5,279 - Quell $2,

  21. Slide 21: Management Team

    Shai N. Gozani, MD., PhD. President, CEO and Founder Thomas T. Higgins SVP and CFO Frank McGillin SVP and General Manager, Consumer Management Team 21 NeuroMetrix, Inc. ©2016 • Extensive public company CFO experience • Strong operational background • 20+ years consumer health care experience • Deep

  22. Slide 22: Investment Highlights

    Investment Highlights • Commercial stage healthcare company combining bioelectrical and digital medicine to address chronic disease • Market a first - in - class over - the - counter wearable device to treat chronic pain • Razor/razor - blade business model with good sales growth in first 6 quarters

NeuroMetrix — IPO Roadshow (November 2016) on 6ix